Abstract: The invention provides particular sets of genes that are expressed differentially in tumors characterized as high MAI or low MAI tumors. These sets of genes can be used to discriminate between high and low MAI tumors. Diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression are also provided.
Abstract: Provided are methods for determining the predisposition of a subject to a mood disorder by determining in a biological sample of a subject, the presence of a kainate receptor subunit GluR7 allelic genotype or allelic phenotype associated with predisposition to a mood disorder. The allelic genotype is homozygosity for a thymine containing nucleotide at position 928 (928T/T) or homozygosity for a guanine containing nucleotide position 928 (928G/G). In addition, a predominant expression of one GluR7 allele over the other allele in a heterozygous individuals also predicts predisposition to a mood disorder. The present invention also includes a method of treating or preventing a mood disorder and methods for identifying a compound useful for treatment. Transgenic non-human animals that express only a particular human GluR7 allele at nucleotide position 928 also are provided as a model of a human mood disorder.
Abstract: The present invention relates to analysis of the alterations in p21waf1/cip1 gene and its expression in relation to p53 status in esophageal cancer, a method for screening of subjects having or at risk of having esophageal cancer by detection of the polymorphism in p21waf1/cip1 gene, and use thereof as a diagnostic marker.
Type:
Grant
Filed:
December 28, 2000
Date of Patent:
September 30, 2003
Assignees:
Council of Scientific and Industrial Research, All India Institute of Medical Sciences
Abstract: The invention features methods for detection of metastatic and potentially metastatic cancerous cells by detection of expression of a gland-specific Ets transcription factor (GSEF) sequence, which encodes an Ets-domain containing protein. The invention also features methods and compositions for modulation of the polypeptide and/or gene activity for prophylactic and therapeutic purposes, such as inhibition of progression of a cell to a metastatic cancerous cell.
Abstract: This invention relates to androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.
Type:
Grant
Filed:
January 26, 2001
Date of Patent:
May 20, 2003
Assignee:
Henry M. Jackson Foundation for the Advancement of Military
Medicine
Inventors:
Shiv Srivastava, Judd W. Moul, Linda L. Xu, Takehiko Segawa
Abstract: The present invention is directed to a tumor suppressor protein which has been designated hamartin and to the gene, TSC1, which encodes this protein. Mutations in the gene have been found to be associated with certain types of tuberous sclerosis and this has served as a basis for a diagnostic method designed to identify patients that have, or are likely to develop, symptoms associated with this disease. The introduction of the TSC1 gene and subsequent expression of hamartin into cells may be used as a means for treating tuberous sclerosis and other conditions characterized by abnormal cellular growth.
Type:
Grant
Filed:
September 12, 2001
Date of Patent:
April 15, 2003
Assignee:
Brigham and Women's Hospital
Inventors:
David J. Kwiatkowski, Julian R. Sampson, Margaret S. Povey, Marjon A. van Slegtenhorst, Dicky J. J. Halley